{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:24:29Z","timestamp":1794306269732,"version":"4.9.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009035","name":"Program on Open Innovation Platform with Enterprises Research Institute and Academia","doi-asserted-by":"publisher","award":["JPMJOP1722"],"award-info":[{"award-number":["JPMJOP1722"]}],"id":[{"id":"10.13039\/501100009035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regenerative Therapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.reth.2026.101176","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:40:50Z","timestamp":1789846850000},"page":"101176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pilot study of Wilms tumor 1-targeted human platelet lysate-induced antigen-presenting cells in advanced solid cancer patients"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7424-4548","authenticated-orcid":false,"given":"Misa","family":"Togi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terutsugu","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1115-8535","authenticated-orcid":false,"given":"Tamaki","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2662-0024","authenticated-orcid":false,"given":"Sohsuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Jang","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-2175","authenticated-orcid":false,"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Koido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-6912","authenticated-orcid":false,"given":"Shigetaka","family":"Shimodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reth.2026.101176_bib1","first-page":"4472","article-title":"T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression","volume":"7","author":"June","year":"1987","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.reth.2026.101176_bib2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4049\/jimmunol.147.8.2461","article-title":"CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells","volume":"147","author":"Jenkins","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib3","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.4049\/jimmunol.153.5.1990","article-title":"Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen","volume":"153","author":"Lenschow","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib4","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.4049\/jimmunol.168.7.3484","article-title":"Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin","volume":"168","author":"Seki","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib5","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2012-07-446146","article-title":"Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack","volume":"121","author":"Lopez","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.reth.2026.101176_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reth.2026.101176_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","article-title":"Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial","volume":"8","author":"Vogelzang","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.reth.2026.101176_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.reth.2026.101176_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.reth.2026.101176_bib10","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood.V88.10.4029.bloodjournal88104029","article-title":"Generation of CD1+RelB+ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes","volume":"88","author":"Akagawa","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.reth.2026.101176_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1479-5876-5-46","article-title":"Monocyte derived dendritic cells generated by IFN-\u03b1 acquire mature dendritic and natural killer cell properties as shown by gene expression analysis","volume":"5","author":"Korthals","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.reth.2026.101176_bib12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1189\/jlb.71.4.669","article-title":"IFN-\u03b12a induces IP-10\/CXCL10 and MIG\/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells","volume":"71","author":"Padovan","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.reth.2026.101176_bib13","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/eji.200535579","article-title":"IFN-\u03b1-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens","volume":"36","author":"Lapenta","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/srep42145","article-title":"Interferon-\u03b1-inducible dendritic cells matured with OK-432 exhibit TRAIL and Fas ligand pathway-mediated killer activity","volume":"7","author":"Koya","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.reth.2026.101176_bib15","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4049\/jimmunol.180.3.1462","article-title":"IFN-\u03b1 skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo","volume":"180","author":"Papewalis","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12967-015-0473-5","article-title":"Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma","volume":"13","author":"Rozera","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.reth.2026.101176_bib17","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1158\/1078-0432.CCR-19-0709","article-title":"Clinical and antitumor immune responses in relapsed\/refractory follicular lymphoma patients after intranodal injections of IFN\u03b1-dendritic cells and rituximab: a phase I clinical trial","volume":"25","author":"Cox","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.reth.2026.101176_bib18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1349-7006.2004.tb02490.x","article-title":"Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma","volume":"95","author":"Oji","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.reth.2026.101176_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00262-018-2257-2","article-title":"Phase I\/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer","volume":"68","author":"Zhang","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.reth.2026.101176_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1744-9987.12831","article-title":"Phase I\/II pilot study of Wilms' tumor 1 peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer","volume":"23","author":"Ogasawara","year":"2019","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.reth.2026.101176_bib21","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1080\/21645515.2021.2003645","article-title":"Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and\/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy","volume":"17","author":"Ota","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.reth.2026.101176_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00262-011-1033-3","article-title":"Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response","volume":"60","author":"Takahara","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.reth.2026.101176_bib23","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1038\/ncomms6852","article-title":"The Wilms' tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression","volume":"5","author":"Wagner","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.reth.2026.101176_bib24","article-title":"Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies","volume":"3","author":"Yokota","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.reth.2026.101176_bib25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2026.101176_bib27","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1073\/pnas.1820388116","article-title":"Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity","volume":"116","author":"Onda","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.reth.2026.101176_bib28","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1002\/eji.201343349","article-title":"Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events","volume":"43","author":"Schouppe","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib29","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","article-title":"Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine","volume":"25","author":"Filipazzi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.reth.2026.101176_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1189\/jlb.0310162","article-title":"Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties","volume":"89","author":"Brandau","year":"2011","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.reth.2026.101176_bib31","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2010-12-325753","article-title":"A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells","volume":"118","author":"Solito","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.reth.2026.101176_bib32","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00262-013-1475-x","article-title":"Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients","volume":"62","author":"Jordan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.reth.2026.101176_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00262-011-1143-y","article-title":"Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines","volume":"61","author":"Poschke","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.reth.2026.101176_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.589434","article-title":"Tumor lactic acidosis: protecting tumor by inhibiting cytotoxic activity through motility arrest and bioenergetic silencing","volume":"10","author":"Fischbeck","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.reth.2026.101176_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/vaccines9010010","article-title":"Interferon-\u03b1-induced dendritic cells generated with human platelet lysate exhibit elevated antigen presenting ability to cytotoxic T lymphocytes","volume":"9","author":"Date","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.reth.2026.101176_bib36","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.3390\/cancers15143627","article-title":"Clinical trial on the safety and tolerability of personalized cancer vaccines using human platelet lysate-induced antigen-presenting cells","volume":"15","author":"Koya","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.reth.2026.101176_bib37","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.reth.2026.101176_bib38","first-page":"1047","article-title":"Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA-A2-restricted WT1-reactive CD8+ T cells","volume":"57","author":"Kan","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.reth.2026.101176_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009765","article-title":"Dendritic cells pulsed with multifunctional Wilms' tumor 1 peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer","volume":"12","author":"Koido","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.reth.2026.101176_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/pharmaceutics12040305","article-title":"Dendritic cells pre-pulsed with Wilms' tumor 1 in optimized culture for cancer vaccination","volume":"12","author":"Koya","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.reth.2026.101176_bib41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.reth.2026.101176_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1935557","article-title":"Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients","volume":"10","author":"Van Wigcheren","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.reth.2026.101176_bib43","first-page":"2217","article-title":"WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study","volume":"38","author":"Yanagisawa","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.reth.2026.101176_bib44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CJI.0000000000000127","article-title":"Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patients","volume":"39","author":"Boudewijns","year":"2016","journal-title":"J Immunother"},{"key":"10.1016\/j.reth.2026.101176_bib45","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/modpathol.3800588","article-title":"Immunohistochemical detection of WT1 protein in a variety of cancer cells","volume":"19","author":"Nakatsuka","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.reth.2026.101176_bib46","first-page":"921","article-title":"Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation","volume":"61","author":"Loeb","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.reth.2026.101176_bib47","first-page":"1167","article-title":"High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients","volume":"8","author":"Miyoshi","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.reth.2026.101176_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nm1039","article-title":"Dendritic cell immunotherapy: mapping the way","volume":"10","author":"Figdor","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.reth.2026.101176_bib49","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X","article-title":"CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells","volume":"30","author":"Cederbom","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1295203","article-title":"Generation and functional characterization of MDSC-like cells","volume":"6","author":"Heine","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.reth.2026.101176_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104918","article-title":"Cryopreservation affected the levels of immune responses of PBMCs and antigen-presenting cells","volume":"67","author":"Martikainen","year":"2020","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.reth.2026.101176_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jim.2004.08.001","article-title":"Implication of delayed TNF-\u03b1 exposure on dendritic cell maturation and expansion from cryopreserved cord blood CD34+ hematopoietic progenitors","volume":"293","author":"Xu","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.reth.2026.101176_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jim.2011.08.010","article-title":"Cryopreservation of monocytes or differentiated immature DCs leads to an altered cytokine response to TLR agonists and microbial stimulation","volume":"373","author":"Meijerink","year":"2011","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.reth.2026.101176_bib54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00262-020-02648-y","article-title":"PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in NSCLC patients","volume":"70","author":"Raniszewska","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.reth.2026.101176_bib55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/cas.12621","article-title":"Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer","volume":"106","author":"Mayanagi","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.reth.2026.101176_bib56","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/0008-5472.CAN-03-4005","article-title":"Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432","volume":"64","author":"Okamoto","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.reth.2026.101176_bib57","article-title":"Infiltration of alternatively activated macrophages in cancer tissue is associated with MDSC and Th2 polarization in patients with esophageal cancer","volume":"9","author":"Gao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.reth.2026.101176_bib58","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41590-019-0429-7","article-title":"Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.reth.2026.101176_bib59","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3390\/jcm13175130","article-title":"Circulating M-MDSC levels as an assessment marker for post-treatment tumor progression in recurrent head and neck cancer patients following radiation therapy: a case series","volume":"13","author":"Chang","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.reth.2026.101176_bib60","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.reth.2026.101176_bib61","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4049\/jimmunol.1900930","article-title":"Tumor microenvironment following gemcitabine treatment favors differentiation of immunosuppressive Ly6Chigh myeloid cells","volume":"204","author":"Wu","year":"2020","journal-title":"J Immunol"}],"container-title":["Regenerative Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320426001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352320426001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:34:07Z","timestamp":1794303247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352320426001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":61,"alternative-id":["S2352320426001173"],"URL":"https:\/\/doi.org\/10.1016\/j.reth.2026.101176","relation":{},"ISSN":["2352-3204"],"issn-type":[{"value":"2352-3204","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot study of Wilms tumor 1-targeted human platelet lysate-induced antigen-presenting cells in advanced solid cancer patients","name":"articletitle","label":"Article Title"},{"value":"Regenerative Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reth.2026.101176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier BV on behalf of The Japanese Society for Regenerative Medicine.","name":"copyright","label":"Copyright"}],"article-number":"101176"}}